Ductal carcinoma in situ: how should we treat it?

By Bayraktar Soley   Arun Banu   Glück Stefan  

Breast Cancer Management, Vol. 2, Iss. 3, 2013-05 ,pp. : 245-256

Future Medicine

Access to resources Recommend Favorite

Cancer therapy: could a novel test predict the amount of drug that reaches its target?

By van der Veldt Astrid AM   Smit Egbert F   Lammertsma Adriaan A  

Expert Review of Anticancer Therapy, Vol. 13, Iss. 4, 2013-04 ,pp. : 377-379

Informa Healthcare

Access to resources Recommend Favorite

“Overcoming breast cancer drug resistance with mTOR inhibitors”. Could it be a myth or a real possibility in the short-term future?

By Margariti Nadia  

Breast Cancer Research and Treatment, Vol. 128, Iss. 3, 2011-08 ,pp. : 599-606

Springer Publishing Company

Access to resources Recommend Favorite

Why not treat human cancer with interleukin-1 blockade?

By Dinarello Charles  

Cancer and Metastasis Reviews, Vol. 29, Iss. 2, 2010-06 ,pp. : 317-329

Springer Publishing Company

Access to resources Recommend Favorite

Drug switch because of treatment-related adverse side effects in endocrine adjuvant breast cancer therapy: how often and how often does it work?

By Güth Uwe  

Breast Cancer Research and Treatment, Vol. 129, Iss. 3, 2011-10 ,pp. : 799-807

Springer Publishing Company

Access to resources Recommend Favorite